Browse Articles

Discover research articles across all indexed journals

Survival outcomes based on line of therapy and treatment trends with cabazitaxel in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology Ayana Srivastava, Yeonjung Jo, Zeynep Irem Ozay et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.162

162 Background: Pts with mCRPC after progression on docetaxel and androgen receptor pathway inhibitors (ARPIs), have limited treatment options. Even with the changing landscape, cabazitaxel remains an effective approved therapy in this setting for these pts. However, real-world data on the efficacy and trends of cabazitaxel usage remain limited. Herein, we aimed to assess the survival outcomes and treatment patterns in pts with mCRPC receiving single-agent cabazitaxel in a real-world setting. Methods: This retrospective study utilized the nationwide Flatiron Health electronic health record (EHR) derived de-identified database. Eligibility: Diagnosis of mCRPC and receipt of single-agent cabazitaxel for the first time. Survival was calculated from the date pts received their first treatment with cabazitaxel. Time to next treatment (TTNT) and overall survival (OS) were summarized using Kaplan Meier survival estimates and its 95% confidence intervals (CI). Results: Among 24,105 pts with metastatic prostate cancer in the dataset, 1,315 pts diagnosed between 1/1/2013 and 1/26/2024 received single-agent cabazitaxel. Median age of pts was 73 years (IQR 67 – 78). The majority were non-Hispanic White (62%), treated in community practice (84%), had commercial insurance (81%), and received treatment in the third line or later (86%). The number of pts receiving cabazitaxel per year steadily increased from 2 (0.2%) in 2012 to a peak of 181 pts (14%) in 2021. Following the approval of lutetium-177-PSMA-617 (Lu) in 2022, cabazitaxel usage declined to 126 pts (9.6%) in 2023, indicating a shift in treatment patterns. The median TTNT was 4.7 months (95% CI, 4.4–5.0), and the median OS was 8.6 months (95% CI, 8.0–9.3) for pts treated with cabazitaxel. Median TTNT and OS by line of therapy are summarized (Table) . Conclusions: Despite proven OS benefit, the overall utilization of cabazitaxel is low in real-world pts in the US. The number of pts with mCRPC receiving cabazitaxel steadily increased until 2021 and declined following the approval of Lu in 2022, highlighting the evolving treatment landscape. Cabazitaxel continues to be an effective therapy regardless of line of therapy. Median TTNT and OS by line of therapy in pts with mCRPC receiving cabazitaxel. Line of therapy Number of pts, n (%) Median TTNT (mo) (95% CI) Median OS (mo) (95% CI) 2 183 (13.9) 5.7 (4.8, 6.3) 11 (9.5, 14) 3 378 (28.7) 4.3 (3.8, 4.7) 7.5 (6.6, 8.4) 4 430 (32.7) 4.5 (4.1, 4.8) 8.5 (7.5, 9.4) 5 219 (16.7) 5.1 (4.4, 5.9) 9.2 (8.0, 12) 6 71 (5.4) 5.1 (4.1, 5.9) 7.7 (5.9, 11) 7 22 (1.7) 6.8 (2.8, 12) 11 (8.2, 18) 8 6 (0.5) 4.9 (1.8, -) 6.3 (1.8, -) 9 6 (0.5) 4.2 (2.8, -) 14 (9.7, -)

A phase 1/2 study of nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC).

Journal of Clinical Oncology Bilal Ahmed Siddiqui, Benedito A. Carneiro, Mark N. Stein et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps293

TPS293 Background: Advanced mCRPC and metastatic ccRCC are urologic malignancies with poor prognoses, and novel therapies that can improve long-term outcomes remain an unmet medical need. Prostate-specific membrane antigen (PSMA) is a validated therapeutic target for prostate cancer. It is a transmembrane protein with enzymatic activity highly expressed by prostate cancer cells and ccRCC neovasculature. Nezastomig (REGN5678) is a first-in-class, PSMA×CD28 co-stimulatory bispecific antibody (bsAb) that facilitates T-cell mediated tumor killing by bridging PSMA-expressing cells with the costimulatory receptor, CD28, on T cells. Preliminary results have been reported from an open-label, Phase 1/2, first-in-human, multicenter study of nezastomig + cemiplimab in heavily pretreated pts with mCRPC (NCT03972657). In the dose escalation phase, nezastomig (30–300 mg) intravenously (IV) once weekly (QW) + cemiplimab (350 mg) IV once every 3 weeks (Q3W) reduced prostate-specific antigen levels and induced radiographic responses, providing the first evidence of clinical activity with a ×CD28 bsAb in solid tumors. The study has been amended to continue evaluation of nezastomig monotherapy in mCRPC based on the observed clinical activity and possible toxicity from the combination. Nezastomig is also being evaluated in pts with metastatic ccRCC. Methods: Pts with mCRPC must have received ≥2 prior lines of systemic therapy approved for metastatic and/or castration-resistant disease, including a second-generation androgen receptor signaling inhibitor. Pts with metastatic ccRCC must have received ≥1 prior line of systemic therapy approved in the metastatic setting, including an anti-programmed cell death-(ligand) 1 therapy and either ipilimumab and/or a tyrosine kinase inhibitor. Nezastomig IV QW monotherapy starting dose for the mCRPC and ccRCC cohorts was informed by tolerability and clinical activity. Dose escalation of nezastomig monotherapy will occur in separate cohorts for mCRPC and ccRCC. When a maximum tolerated dose/presumptive recommended Phase 2 dose is identified, additional expansion cohorts may be evaluated. In pts with progressive disease after ≥6 weeks of nezastomig monotherapy, low-dose cemiplimab IV Q3W may be added. Dose escalation primary objectives are to determine safety, tolerability, and pharmacokinetics of nezastomig. Dose expansion primary objective is to assess efficacy of nezastomig (measured by objective response rate per modified Prostate Cancer Working Group 3 criteria [mCRPC cohorts] and per Response Evaluation Criteria in Solid Tumors version 1.1 [ccRCC cohorts]). The study is open and enrolling; 101 pts (97 with mCRPC; 4 with ccRCC) have been enrolled as of September 12, 2024. Clinical trial information: NCT03972657 .

Real world effectiveness of systemic treatment in patients (pts) with advanced upper tract urothelial carcinoma (UTUC) with histological variants.

Journal of Clinical Oncology Fabien Moinard-Butot, Karim Amrane, Luca Campedel et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.722

722 Background: Upper tract urothelial carcinoma is a rare and heterogeneous disease that accounts for up to 5% of all urothelial neoplasms. Variant histology is an important prognostic factor in patients affected by bladder cancer and its presence is associated with adverse pathological features and worse survival outcomes. However, few data exists regarding the impact of histological variants in patients affected by UTUC treated with systemic therapy. Methods: PEMBROBLAD is a retrospective multicenter RW study conducted in 24 French GETUG centers. Eligible patients had advanced UC with mixed variants (UC-V) or pure non-UC (NUC). All patients received ICI as a second line treatment. We identified all patients with UTUC within the whole study cohort. The primary endpoint was overall response rate (ORR) in first-line setting; secondary endpoints included disease control rate (DCR) in first-line setting, overall response rate (ORR) in second-line setting, DCR in second-line setting and overall survival (OS). Results: Out of 139 patients (pts) in the PEMBROBLAD cohort, 32 had UTUC. Median age was 72 years (range 49-88), 69.6 % were male with ECOG PS 0/1 in 64.5% of cases. Mixed UC represented 75% (n=24) of UTUC with histological variants. The most common were squamous cell carcinoma (n=9, 37.5%), micropapillary (n=7, 29.2%), sarcomatoïd (n=3, 12.5%), neuroendocrine (n=1, 4.2%), nested (n=4, 16.7%) and adenocarcinoma (n=3, 37.5%). Non UC concerned 25% (n=8) of UTUC with histological variants, including 4 patients with squamous cell carcinoma (n=4, 50%). Fifteen pts (46.9%) was treated with Carboplatin based combination in first-line and 14 pts (43.75%) with Cisplatin based treatment. The ORR was 33.3% and DCR was 50.0%. All patients received immunotherapy in second-line setting. The ORR was 18.7% and DCR was 28.1%. Median overall survival from first-line treatment is 8.9 months (CI95%, 3.6-18.5). Serious TRAE occurred in 5 pts (16.1%). Discontinuation due to TRAEs occurred in 9.6% of pts. Thirteen pts (41.9%) had a third-line of treatment. Conclusions: Our results suggest efficacy of chemotherapy in first-line setting and ICI in pretreated advanced UC-V and NUC. No new safety concerns were identified. Survival data will be updated for the meeting.

Discordance in HER2 expression in primary and recurrent/metastatic lesions of upper tract urothelial carcinoma: A study focusing on temporal heterogeneity.

Journal of Clinical Oncology Jianjun Ye, Xinyang Liao, Qihao Wang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.839

839 Background: The promising performance of HER2 antibody–drug conjugates (ADC) in clinical trials suggested that HER2-targerted therapy, particularly ADCs, may be a suitable treatment option for metastatic UTUC. However, we have observed cases where ADCs were ineffectiveness for recurrent/metastatic lesions in patients with HER2-positive primary UTUC. Thus, we conducted a retrospective study of UTUC patients to investigate the specific HER2 expression in paired primary and recurrent/metastatic lesions. Methods: Data of 290 UTUC patients who underwent radical nephroureterectomy at West China Hospital of Sichuan University from Jan 2020 and Oct 2023 without neoadjuvant treatment were retrospectively included. The HER2 expression was independently evaluated through immunohistochemistry by our professional genitourinary pathologists. HER2 2+ and HER2 3+ were considered HER2-positive whereas others were considered HER2-negative. Results: A total of 249 patients had HER2 expression evaluation of their specimens, with 92 patients (39.36%) showing HER2-positivity (IHC HER2 2+ or 3+). During rigorous follow-up, 31 patients (12.45%) developed local recurrence or distant metastasis. The majority of those patients had locally advanced UTUC (pT ≥ 3) and high grade disease. We observed discordance in HER2 expression between primary and recurrent/metastatic lesions in 22 cases (70.97%), with 9 cases (29.03%) showing an increase in HER2 expression and 13 cases (41.94%) showing a loss of HER2 expression. The conversion from HER2 negative to positive or vice versa occured in 5 cases (16.13%) and 10 cases (32.26%), respectively. Notably, all primary lesions with HER2 0 expression obtained HER2 expression in recurrent/metastatic lesions (5/5, 100%). Conclusions: Our findings highlight the discordance in HER2 expression between primary and recurrent/metastatic lesions in UTUC, underscoring the need for further investigation and potential modifications in disease management.

Erratum: Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update

Journal of Clinical Oncology Feb 10, 2025 DOI: 10.1200/jco-24-02719

AVENANCE real-world study of avelumab first-line (1L) maintenance treatment for advanced urothelial carcinoma (UC): Analyses in low tumor burden subgroups.

Journal of Clinical Oncology Philippe Barthélémy, Yohann Loriot, Constance Thibault et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.718

718 Background: The effectiveness and safety of avelumab 1L maintenance was confirmed in the large real-world AVENANCE study in France. In patients with advanced UC, low tumor burden is associated with a better prognosis, which may inform treatment decisions. Here, we report post hoc analyses from AVENANCE in subgroups with disease characteristics associated with low tumor burden. Methods: AVENANCE (NCT04822350) is a noninterventional ambispective study that enrolled patients with locally advanced or metastatic UC who were progression free after 1L platinum-based chemotherapy (PBC) and who had previous, ongoing, or planned avelumab 1L maintenance treatment. The primary endpoint is overall survival (OS) from the start of avelumab treatment. In post hoc analyses, OS and progression-free survival (PFS) were analyzed in subgroups who had locally advanced disease, nonvisceral metastases (excluding bone), or lymph node (LN)–only disease at the start of PBC. Results: Of patients with available data in the overall effectiveness population (N=595), 49 (8.3%) had locally advanced disease, 80 (14.7%) had nonvisceral metastases, and 61 (10.3%) had LN-only disease. At data cutoff (July 15, 2024) in the overall effectiveness population, median follow-up from start of avelumab was 33.2 months (95% CI, 31.7-34.2), median OS was 21.2 months (95% CI, 17.3-23.3), and median PFS was 5.7 months (95% CI, 5.2-6.6). In subgroups with locally advanced disease, nonvisceral metastases, or LN-only disease, median OS (95% CI) was not reached (17.4 months-not estimable [NE]), 27.2 months (16.8-NE), and not reached (19.9 months-NE), and median PFS (95% CI) was 19.8 months (9.6-NE), 9.0 months (5.8-16.1), and 13.4 months (6.9-26.5), respectively. Subsequent treatment was received by 17 patients (34.7%) with locally advanced disease (enfortumab vedotin [EV] in 3 [6.1%]), 45 patients (56.3%) with nonvisceral metastases (EV in 12 [15.0%]), and 33 patients (54.1%) with LN-only disease (EV in 8 [13.1%]). Conclusions: Subgroup analyses from AVENANCE show pronounced clinical benefits with avelumab 1L maintenance in subgroups with low tumor burden characteristics. Results are consistent with previous analyses from JAVELIN Bladder 100 and other real-world studies (eg, READY, an Italian compassionate use program) and further support the use of avelumab 1L maintenance as a standard of care in patients with advanced UC without progression after 1L PBC, including those with low tumor burden. Clinical trial information: NCT04822350 .

A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).

Journal of Clinical Oncology Feng Wen, Tianhai Lin, Ping Tan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.795

795 Background: To evaluate the safety and efficacy of RC48-ADC, a humanized anti-HER2 antibody conjugated with monomethyl auristatin E, and tislelizumab, a PD-1 antibody, as a novel neoadjuvant treatment combination in patients with HER2 positive locally advanced muscle-invasive bladder cancer (MIBC). The study design has been presented at 2022 ESMO Asia meeting, and preliminary results will be reported this time. Methods: This is a Ib/II, multi-center, open-label, single-arm study (ChiECRCT20210564). Patients with pathological and imaging diagnosed cT2-4bN0-3M0-1a HER2 positive (Immunohistochemistry status 3+ or 2+ or 1+) MIBC. Of them, 6 patients are enrolled in the dose-escalation phase, and 45 patients enter into phase II study. RC48-ADC is given every 2 weeks with a maximum dose of 120mg intravenously, and tislelizumab is given every three weeks at the dose of 200mg intravenously. Patients without disease progression will receive radical cystectomy or bladder-sparing therapies based on individual risk profiles and preferences. The primary endpoints are clinical complete remission rate (cCR, T0/Ta/Tis), pathological complete remission rate (pCR) and safety. Results: Inclusion has been closed, with a total of 51 patients successfully enrolled, consisting of 7 females and 44 males. The median age was 70 ± 10.16 years. Among the participants, 3 patients were HER2(1+), 26 patients were HER2(2+), and 22 patients were HER2(3+). The median follow-up duration was 12.8 ± 1.81 months. A total of 46 patients underwent primary efficacy evaluation after neoadjuvant treatment: 26 patients cCR, 14 patients partial response (PR), 2 patients stable disease (SD), and 4 patients disease progression. The cCR rate was 56.52%, and the disease control rate (DCR) was 91.30%. Of the 51 patients, 36 opted for radiotherapy as bladder-sparing therapy, resulting in 1 patient achieving Tis and 35 achieving T0 after radiotherapy. Three patients have passed away so far, and the 18-month survival rate was 100%. Regarding safety, 7 patients experienced immune-related adverse events, including grade 2 myositis, grade 1 elevated transaminase, and grade 1 hyperthyroidism, which led to an interruption of tislelizumab treatment. Additionally, 10 patients experienced RC48-ADC-related toxicities, including grade 1 elevated transaminase, grade 2 erythema, and grade 2 paresthesia. Two treatment-related interruptions occurred. Conclusions: The novel neoadjuvant combination of RC48-ADC and tislelizumab demonstrated promising downstaging efficacy in patients with HER2-positive locally advanced MIBC and provides an opportunity for radiotherapy-based bladder-sparing treatment. The toxicities observed were manageable, and the long-term efficacy of bladder preservation will be confirmed in the final analysis. Clinical trial information: ChiECRCT20210564.

Prospective real world data evaluation of clinical outcomes in metastatic hormone sensitive prostate cancer (MHSPC) patients treated as part of triplet therapy with darolutamide: UK multicenter RECOMMEND study.

Journal of Clinical Oncology Amit Bahl, Amarnath Challapalli, Prantik Das et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.89

89 Background: Darolutamide has authorisation for treatment of metastatic hormone sensitive prostate cancer (MHSPC) in combination with docetaxel chemotherapy and androgen deprivation therapy (triplet therapy) based on ARASENS trial results. The RECOMMEND study is a prospective real-world evaluation (RWE) of clinical outcomes in patients with MHSPC treated with this regimen in the UK. Methods: 318 patients were enrolled from 21 UK centres over 20 months from November 2022. Data cut-off was 14 August 2024. Disease characteristics were evaluated. Descriptive statistics have been used for patient demographics and PSA changes with treatment were analysed. Results: Patients on the study had a median age of 67 (range 38-84) years. Majority of the patients were de novo metastatic (91.2%). 68.2% have a Gleason score ≥8. 76 patients (23.9%) had next generation imaging (NGI) at diagnosis. Performance score was 0 (62.7%) or 1 (37.3%). The distribution of metastases (%) were: bone (84.9), nodal (60.4), lung (12.6) and liver (2.5). The median PSA level was 134 (range 1 to 5628) ng/mL at diagnosis. At the end of docetaxel chemotherapy median PSA was 0.35 ng/mL. PSA response see in the 226 patients who had completed 6 cycles of docetaxel chemotherapy at the data cut-off, PSA 50 was seen in 87.6% (198/226) and PSA 90 in 53.2%. PSA responses in those who only completed 4/5 cycles of docetaxel (n=14) did not significantly differ compared to those who completed all 6 cycles (PSA 50 p=0.445 and PSA 90 p-0.664). At 6 months from darolutamide initiation, quality of life (QoL) data is currently available for 173 patients, of these 88.4% reported either stable or improved QoL and 11.6% had a decline in QoL at the end of chemotherapy. Conclusions: The tolerability and efficacy profile of treatment with ADT+Darolutamide+Docetaxel in MHSPC in the RECOmMEnD study is similar to that reported in the ARASENS trial. The QoL data available for 173 patients to date reports either stable or improved QoL at 6 months for 88.4% cases. This provides important prospective RWE data, enabling patients and clinical teams to make informed choices in this setting.

Androgen receptor activity in biopsy specimens at initial diagnosis of prostate cancer and correlation with outcomes and treatment response.

Journal of Clinical Oncology Nicole Handa, Mohammed Alshalalfa, Yangyang Hao et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.409

409 Background: Androgen receptor activity (AR-A) has been described after radical prostatectomy (RP) and metastatic castration-sensitive prostate cancer (mCSPC). In RP specimens low AR-A is associated with basal subtypes, decreased DNA repair and increased immune activity. In mCSPC, low AR-A is associated with poor overall survival (OS) and time to progression to CRPC. However, AR-A has not been well characterized in localized disease at initial diagnosis. Here we sought to assess AR-A signatures in biopsy samples from patients across the prostate cancer risk continuum and assess correlations between AR-A and outcomes. Methods: We analyzed 150,162 biopsy samples tested (2016-2024) with the Decipher prostate genomic classifier (Veracyte, Inc. San Diego, CA). Transcriptome-wide expression data and clinical factors were retrieved from the Decipher GRID (NCT02609269). Patients with low and high AR-A expression as defined by Spratt et al 2019 were compared using Chi-square tests. Clinical and pathologic outcomes for specific cohorts in the overall sample population were analyzed using Cox regression. Results: Overall, 11,752 (7.8%) patients had low AR-A expression. 9.8% of patients > 70 years of age had low AR-A compared to 7.6% of patients <70 (p<0.0001). Low AR-A was enriched in samples with poor prognostic clinical factors such as very high Decipher (p<0.0001), Grade Group (GG) 5 (p<0.0001) and very high NCCN risk (p<0.0001). The same differences were present when looking only at patients with a PSA <4 ng/mL. Like in RP samples, AR-A expression in biopsy samples positively correlated with intact DNA repair and negatively correlated with basal subtypes, PORTOS and immune infiltration scores (all p<0.001). Low AR-A was prognostic of poor clinical outcomes across 4 independent retrospective cohorts. In cohort 1, intermediate risk disease (n=647), low AR-A correlated with adverse pathology at time of RP (p <0.05). In cohort 2, intermediate risk disease treated with radiation therapy (RT) (n=121), low AR-A correlated with biochemical failure (p<0.05). In cohort 3, high risk disease (n=405), low AR-A correlated with decreased OS (p<0.05) in all patients and metastasis (p<0.05) after RT and androgen deprivation therapy (ADT). Finally, in cohort 4, high risk disease treated with RT+ADT (n=100), low AR-A correlated with metastasis (p<0.01). Conclusions: Overall, in a large cohort of biopsy specimens, low AR-A was associated with increased age, very high Decipher score, very high NCCN risk, and GG5 disease. Subpopulation analyses suggest that low AR-A portends a poor prognosis. Given that patients with low AR-A had decreased DNA repair activity and increased PORTOS scores, clinicians should consider post-operative RT and novel clinical trials with PARP inhibitors for these patients.

Global spatiotemporal trends in prostate cancer burden and its socioeconomic disparities: An observational study from 1990 to 2021.

Journal of Clinical Oncology Xianghong Zhou, Qiang Wei Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.325

325 Background: Prostate cancer is the second most common cancer in men globally, posing significant health challenges. Conflicting findings on its global burden and trends necessitate updated analyses. This study provides recent estimates of prostate cancer's global, regional, and national burden from 1990 to 2021, analyzes temporal trends, and offers epidemiological insights for clinicians, researchers, and policymakers. Methods: We analyzed data from the Global Burden of Disease Study 2021 on prostate cancer cases, deaths, and disability-adjusted life years (DALYs) from 1990 to 2021, including age-standardized rates (ASRs) for incidence, mortality, and DALYs. Trend analyses utilized average annual percent change (AAPC) calculations and joinpoint regression models. Age-period-cohort analysis assessed the effects of age, period, and cohort on incidence and mortality trends. Pearson correlation evaluated associations between ASRs and the Socio-demographic Index (SDI) to explore socioeconomic impacts. Results: From 1990 to 2021, global prostate cancer cases, deaths, and DALYs increased, reflecting aging populations. The age-standardized incidence rate (ASIR) showed a slight global increase (AAPC = 0.15, 95% CI: 0.05–0.25), while the age-standardized mortality rate (ASMR) and age-standardized DALY rate (ASDR) decreased (ASMR AAPC = -0.83, 95% CI: -0.92 to -0.74; ASDR AAPC = -0.75, 95% CI: -0.82 to -0.68), indicating improved survival. High-SDI regions had decreasing ASMR and ASDR despite high ASIRs due to better detection and treatment. Low-SDI regions saw increases in ASIR, ASMR, and ASDR, with the highest mortality and DALY rates, indicating rising burden and potential healthcare access issues. Joinpoint regression showed initial increases then decreases in ASIR, ASMR, and ASDR, with regional differences in timing. Age-period-cohort analysis revealed age effects with rising incidence and mortality risks, declining incidence risk in the oldest age groups. Period effects showed incidence risk increasing until 2011–2017, then declining; mortality risk decreased over time. Cohort effects showed stable then increasing incidence risk in younger cohorts, while mortality risk decreased across cohorts, reflecting healthcare improvements. Conclusions: The global absolute burden of prostate cancer has increased, but age-standardized mortality and DALY rates have decreased, especially in high-SDI regions due to advancements in detection and treatment. Low-SDI regions face rising incidence and mortality, highlighting growing disparities. Targeted interventions and resource allocation in low-SDI regions are needed to address the increasing burden and reduce global health inequalities.

Development of a FKSI-23: A new bespoke health-related quality of life (HRQOL) questionnaire for the advanced and adjuvant setting in renal cell carcinoma (RCC).

Journal of Clinical Oncology Cristiane Decat Bergerot, Paulo Gustavo Bergerot, Daniela V. Castro et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.526

526 Background: Existing HRQOL measures may not fully capture the experiences of patients with localized and advanced RCC. This study aimed to develop a validated, patient-centered HRQOL metric by incorporating insights from patients, advocates, and clinical experts for both localized and advanced RCC. We previously developed a questionnaire for advanced RCC (Bergerot et al., JCO 2024). In this study, we integrate it into the FKSI-19 model and create a new questionnaire. Methods: A four-phase approach was used. Previous work in advanced RCC assessed item relevance from established HRQOL measures (FKSI-19, EORTC QLQ-C30, EQ-5D), refined through patient feedback and expert review. This phase expanded to include localized RCC in the adjuvant setting. In Phase 1, patients with localized RCC rated the the relevance of 54 items from the metastatic cohort. Phase 2 included a panel of 11 expert refining the adjuvant-specific items. Phase 3 gathered feedback from patient advocates, and Phase 4 further refined the items by harmonizing them with the FACT library for consistency across RCC stages. Results: In Phase 1, 6 of 54 items were rated as most relevant by patients with localized RCC. Phase 2 refined these further, excluding redundant items and adding 4 new questions focused on adjuvant therapy. Phase 3 led to minor revisions after advocate review, and Phase 4, the new items were harmonized with validated FACT library questions. The final adjuvant-specific questionnaire comprises 10 items, addressing concerns such as long-term side effects, surveillance anxiety, and post-surgery emotional distress. The advanced-specific version includes 13 items. Both versions deemed to be of utmost importance to patients with localized and advanced disease. These items can be used as standalone scoring options, resulting in the creation of a novel FKSI-23 metric, allowing for customized questionnaires tailored to specific clinical scenarios. Conclusions: Through collective input from patients, advocates and experts, novel items that aid in capturing the experience of RCC patients were identified and existing metrics were refined to generate separate “scoring options” for patients with localized and metastatic disease. Validation of the resulting FKSI-23 tool is underway in forthcoming studies in RCC.

Safety and efficacy of salvage lymph node dissection in prostate cancer patients with nodal recurrence after radical prostatectomy: A prospective single center phase I/II study.

Journal of Clinical Oncology Nicolai A Huebner, Bernhard Grubmueller, David D'Andrea et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.149

149 Background: Optimal management of pelvic nodal recurrence of prostate cancer after RP detected by PSMA-PET is still unclear, although a significant change in treatment due to early use of PET in the setting of BCR has been shown in multiple trials. As pelvic nodal recurrence can be seen as a “in between” state of disease before metastatic disease, metastasis directed therapy could improve oncological outcomes in the long term or at least delay the use of systemic treatment. Salvage Lymph node dissection (sLND) has been described in retrospective trials as effective with biochemical response in up to 60% of patients and long term BCR-free survival of up to 20%. Aim of this study was to prospectively evaluate safety as well as biochemical response to sLAE. Methods: In this study we prospectively included 71 patients with PET detected pelvic nodal recurrence after RP. Uptake in the prostatic fossa, previous pelvic radiation and short-term ADT were allowed. Patients with extra-pelvic metastasis, ECOG ≥2 or thromboembolic event within the last 6 months were excluded. Patients received complete bilateral open sLND. The resection margins were cranially the aortic bifurcation up to the level of the IMA, laterally the genitofemoral nerve, caudally the inguinal ligament or Cloquet's lymph node, medially the urinary bladder, and dorsally the pelvic wall. The obturator fossa was excised with exposure of the obturator nerve and removal of the presacral lymph nodes down to the periosteum. The primary endpoints of the study were safety measured by complication-rate and biochemical response to sLAE by PSA. Results: The median follow-up was 40 months. At the time of surgery median PSA was 1.20ng/ml (IQR 0.79-2.69) and the median number of positive spots on PET was 2 (IQR1-3). Overall, 30% patients showed biochemical remission defined as PSA <0.01. Within the follow up 90% (n=63) of patients experienced biochemical progression. The median time from sLND to BCR and additional treatments was 2 months (95%CI 2 – 5) and 12 months (95%CI 9 – 24) respectively. The median number of LNs removed was 39 and the most common site of relapse was the pelvis. Severe postoperative complications were rare yet did occur with 5 patients experiencing Clavien 3,4 and 5 complications of which one was a bilateral central pulmonary embolism which resulted in the death of the patient. Conclusions: Progression and additional treatments can be delayed with the use of sLAE, however long-lasting biochemical remission was rare. Certain patients with good initial PSA response were able to avoid systemic treatment. While mostly safe, severe side-effects did occur. Due to the potential complications of the surgery, it should be reserved for highly selected cases. Additional trials evaluating criteria for patient selection are important to further explore the potential benefit of sLAE. Clinical trial information: NCT02974075 .

Impact of liquid biopsies on early detection, monitoring, and prognostication in prostate cancer: A meta-analysis of emerging evidence.

Journal of Clinical Oncology Muhammad Nabeel Saddique, Atif Hussain Sarwar, Hashim Talib Hashim et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.32

32 Background: Prostate cancer remains a leading cause of cancer-related morbidity and mortality among men worldwide. Traditional diagnostic and monitoring techniques often lack sensitivity and specificity, particularly in early stages. Liquid biopsies, which analyze circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from blood samples, have emerged as a promising non-invasive alternative for early detection, monitoring disease progression, and prognostication in prostate cancer. Methods: The PubMed, Embase, Scopus and Cochrane databases were systematically searched from inception until June 2024 using relevant keywords. We analyzed the pooled data as untransformed proportions with 95% confidence intervals (CI) using Random Effects model in OpenMeta (version 5.3). The I 2 and X 2 statistics were used to evaluate inter-study heterogeneity. An I 2 value of >50% was considered significant heterogeneity. Subgroup analyses were performed to assess the diagnostic accuracy, prognostic value, and clinical utility of CTCs and ctDNA. Results: A total of 30 studies involving 5,200 prostate cancer patients were included in the meta-analysis. Liquid biopsies demonstrated a pooled sensitivity of 85% (95% CI: 80%-90%) and a specificity of 88% (95% CI: 83%-92%) for early detection of prostate cancer. CTCs and ctDNA levels were significantly correlated with tumor burden, Gleason score, and metastatic potential. Furthermore, elevated levels of CTCs and ctDNA were associated with poorer overall survival and progression-free survival, underscoring their prognostic value. Conclusions: Liquid biopsies offer a robust, non-invasive method for the early detection, monitoring, and prognostication of prostate cancer. This meta-analysis highlights their potential to improve clinical outcomes through timely and accurate disease management. Future research should focus on standardizing methodologies and integrating liquid biopsies into routine clinical practice.

A phase III single-arm study to evaluate the efficacy and safety of paclitaxel-hyaluronic acid conjugate administered intravesically to patients with BCG-unresponsive carcinoma in situ of the bladder with or without Ta-T1 papillary disease (Orion-BC study).

Journal of Clinical Oncology Max Kates, Stephen Bardot, Félix Guerrero-Ramos et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps885

TPS885 Background: Non-muscle invasive bladder cancer (NMIBC) is the most common bladder cancer, with Carcinoma in situ (CIS) being a precursor to muscle-invasive disease. Intravesical BCG is the first-line treatment for high-risk NMIBC, including CIS; however over 50% of patients experience recurrence. Radical cystectomy (RC) is recommended for patients with BCG-unresponsive CIS, but it is associated with high morbidity and mortality. Consequently, some patients are ineligible or decline this option, posing a challenge in the management of the disease. Currently, there is a lack of alternative treatments for patients with BCG-unresponsive CIS in Europe, highlighting an unmet clinical need, while FDA-approved treatments are associated with significant adverse events (AEs). A new conjugate of hyaluronic acid (HA) and paclitaxel (Oncofid-P-B) enhances intracellular drug concentration up to 800-fold by targeting CD44, overexpressed on bladder cancer cells. In a phase I clinical trial, the conjugate showed promising complete response rates (CRR) of 75% at the end of the induction, and of 40% at the end of one-year maintenance phase in patients with BCG-unresponsive CIS, with no significant Grade 3-5 AEs (Hurle 2021). Methods: This is a phase III, single-arm, multicenter study (Clinical trial ID: NCT05024773) assessing the efficacy and safety of intravesical instillations of Oncofid-P-B in BCG-unresponsive patients with CIS +/- Ta-T1 unfit or refusing RC. The study is ongoing at 34 centers in Europe and the US (8 in Italy, 11 in Spain, 7 in France, 3 in Poland, 5 in US). Patients receive 12 weekly intravesical instillations of the drug (600 mg) (induction phase), followed by 12 monthly instillations in those achieving a CR (maintenance phase). Eligibility criteria include an ECOG performance status of 0-2 and persistent or recurrent CIS +/- Ta-T1 within 12 months post-BCG. Tumor response is evaluated by cystoscopy and cytology at the end of the induction, every 3 months for up to 24 months during the maintenance/follow-up, and every 6 months for additional two years. Biopsies are performed at the end of the induction and in case of positive cystoscopy/cytology during treatment and follow-up. Random biopsies are conducted at 9, 15, and 21 months in responding patients. Primary efficacy objective is to evaluate the antitumor activity with centrally assessed CRR following induction. Secondary efficacy objectives include measures of CR rates, duration of response, progression rates, time to progression, and cystectomy rates. Safety evaluation over the study represents the safety objective. The study is currently enrolling in Europe and US. So far, 63 patients were screened and 49 were enrolled (Ta/T1 subgroup: 10 subjects). Clinical trial information: NCT05024773 .

Comparing the effectiveness of IO-based combination regimens as first-line treatment for advanced clear-cell renal cell carcinoma (ccRCC).

Journal of Clinical Oncology Ramona Stelmach, Stefanie Zschaebitz, Stella Erdmann et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.498

498 Background: IO-based combination therapies - either in combination with tyrosine kinase inhibitors (TKI) or as double checkpoint inhibition - have revolutionized first-line treatment of ccRCC patients. We compared tolerability and effectiveness of ipilimumab plus nivolumab (ipi/nivo), cabozantinib plus nivolumab (cabo/nivo), axitinib plus pembrolizumab (axi/pem), and lenvatinib plus pembrolizumab (len/pem) as first-line treatment in real-world cohorts. Methods: Data from retrospective, multicenter cohorts of advanced ccRCC patients were analyzed. Best response was evaluated by local investigators. Adverse events (AE) were assessed according to CTCAE v5.0. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. The log-rank test was used to calculate statistical differences between the cohorts. Results: A total of 543 patients were included in this analysis. Median age of all patients was 65 years (range 21-88), most patients were male (70%). Median number of affected organs were 2 and sites of metastases were comparable between treatment regimens. Key data on IMDC risk group distribution, median follow-up (FU), best response, disease control rate, median PFS, median PFS by IMDC risk group, 1-year OS-rate and occurrence of AEs by treatment regimens are depicted in the table. PFS was significantly superior for IO/TKI combinations compared to Ipi/Nivo (p=0.021). At a median FU of 21.2 months (95%CI 19.7-22.7) for all patients, 51% of patients had disease progression and 26% of patients died. Conclusions: IO/TKI combinations demonstrated significantly better PFS compared to IO/IO as first-line treatment for ccRCC patients. However, no specific IO/TKI regimen showed clear superiority over others, and 1-year OS rate was encouraging across all cohorts. Factors such as IMDC risk, comorbidities, AE profiles and individual treatment goals should be considered when tailoring therapy. Key limitations include the retrospective design, which introduces potential selection and recall biases, varying cohort sizes, the different and limited follow-up time between cohorts and limited OS events. Ipi/Nivo(n=251) Cabo/Nivo(n=47) Axi/Pem(n=118) Len/Pem(n=127) IMDC risk group- fav. risk- int./poor risk 8%92% 34%60% 24%72% 27%73% Median FU in mo. (95%CI) 32.1 (27.5-36.7) 14.0 (10.1-17.8) 22.5 (19.7-25.3) 14.7 (11.3-18.1) Best Response (CR rate) 40% (10%) 49% (2%) 64% (7%) 67% (7%) Disease control rate 64% 68% 86% 78% Median PFS (95%CI)- IMDC fav. risk- IMDC int./poor risk 9.0 (5.8-12.2)7.3 (6.9-7,7)9.7 (6.3-13.1) 16.1 (4.9-27.3)13.0 (6.8-19.2)10.7 (n.e.) 16.8 (10.4-23.2)25.4 (10.0-40.8)12.9 (9.4-16.4) 22.2 (11.7-23.7)22.2 (15.6-28.8)12.2 (0-24.6) 1 y OS rate (95%CI) 81.0 (75.8-86.2) 78.0 (63.8-92.2) 90.6 (84.8-96.4) 78.7 (70.5-86.9) AEs any grade 78% 79% 92% 95% AEs ≥ grade 3 40% 47% 47% 61%

Extreme bipolar androgen therapy: Alternating darolutamide and testosterone cypionate in patients with metastatic castration-resistant prostate cancer (mCRPC; ExBAT trial/LACOG 0620).

Journal of Clinical Oncology Pedro Isaacsson, Andrey Soares, Denis Leonardo Fontes Jardim et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.178

178 Background: Sequencing androgen-receptor signaling inhibitors (ARSi) has limited activity in metastatic castration-resistant prostate cancer (mCRPC). Bipolar Androgen Therapy (BAT), consisting of supraphysiological doses of exogenous testosterone, followed by a decline to castrate levels, has shown benefit in a subset of patients (pts) with mCRPC, by the downregulation of AR levels, a therapeutic vulnerability which led to resensitization to ARSi in trials. We hypothesize that BAT could significantly enhance the efficacy of subsequent ARSi darolutamide in pts who had progressed to abiraterone. Methods: The ExBAT/LACOG 0620 ( NCT04558866 ) study is a phase II, single-arm, multi-center trial investigating a pre-planned regimen of alternating BAT and darolutamide in mCRPC pts after progression on abiraterone. Prior docetaxel for hormone-sensitive disease was allowed. Pts received intramuscular testosterone cypionate 400 mg on day 1, followed by oral darolutamide 1200 mg/day from day 29 to day 56, followed by a washout period of 7 days, in 63-day cycles. The primary endpoint was radiographic progression-free survival (rPFS) at 12 months. Secondary endpoints include median rPFS, PSA50 response, overall survival (OS), quality of life (QoL) and safety. Results: From Jun2021 to Mar2023, 51 pts were enrolled in 9 centers and 48 pts were eligible for efficacy analysis. Median age was 69y (range, 48-92), 23.5% had received abiraterone on castration-sensitive setting and 76.5% on mCRPC. The rPFS rate at 12 months was 40.9% (95% CI, 26.3 – 55.0) and median rPFS was 9.0 months (95% CI, 3.9 – 12.9). PSA50 response was 16.7% (95% CI, 7.4–30.2) and median OS was 23.0 months (95% CI, 17.7 – not reached). At cut-off date (22Mar24), 10 pts remained on treatment. QoL was maintained during the treatment. Treatment-related adverse events (TRAEs) rates of any grade and grade 3-4 were 64.7% and 9.8% respectively, and no grade 5 TRAE was reported. The most common AEs were bone and breast pain. Conclusions: ExBAT study demonstrated durable (12 months or more) antintumor activity of alternating BAT and darolutamide in around 40% of pts, with manageble safety profile. Further studies evaluating ExBAT are needed to identify biomarkers of response and the impact of ARSi sequencing in subsequent lines of therapy. Clinical trial information: NCT04558866 .

EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma.

Journal of Clinical Oncology Amit Bahl, Amarnath Challapalli, Balaji Venugopal et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.1

1 Background: Platinum-based combination chemotherapy remains the Standard of Care (SoC) treatment for patients with locally advanced/metastatic penile cancer (la/mPC). Prognosis is poor and treatment options are limited. PDL1 is upregulated in 40–60% of cases making a case for immunotherapy as a treatment option for la/mPC. PD-1 inhibitor cemiplimab is approved for patients with locally advanced or metastatic cutaneous SCC. We evaluated efficacy and safety of cemiplimab in combination with SoC chemotherapy in patients with la/mPC. Methods: EPIC-A is a National Cancer Research Network badged phase II non-randomised multi-centre trial evaluating the efficacy and safety of cemiplimab plus platinum-based chemotherapy as first-line treatment in la/mPC. Patients with la/mPC (Tany,N2-3,M0 or T4,Nany,M0 or M1) not amenable for radical treatment received: cemiplimab 350mg IV D1 every 3 weeks (Q3W) + SoC chemotherapy cisplatin/5FU (PF, 27 patients) or docetaxel, ifosfamide, cisplatin (TIP, 2 patients) for 4 cycles followed by cemiplimab alone 350mg IV Q3W up to a total of 34 cycles. The primary end point was investigator assessed Clinical Benefit Rate (CBR) at 12 weeks using RECIST 1.1. The study was designed as an A’Hern (2001) study α=0.05 + power (1-β)=0.8, assuming 25% meeting the clinical end point is a poor treatment (p0=0.25) and 50% is a good treatment (p1=0.5). Assuming a 10% drop out rate, 29 patients were recruited. Results: 29 patients from 11 UK sites were enrolled from Jan 2022- Dec 2023. Median age was 61 years (range 38-76). 93% were ECOG 0-1 and 7% ECOG 2. 76% had metastatic disease (6 bone 23%, 2 liver 6.9%, 16 lung 55.2%). Median number of cycles was 5 (range 1-34) and median follow-up was 8.3 (IQR 5.5-11.5) months. At 12 weeks CBR was 62.1% (95%CI 44.4%, 79.7%) and Objective Response Rate (ORR) was 51.7% (95%CI 34.4%, 68.6%) with 15 PR and no CR. Benefit was maintained at 21 weeks with CBR 48.3% (95%CI 31.4%, 65.6%) and ORR 44.8% (95%CI 28.4%, 62.4%) with 12 PR and 1 CR. Median Progression Free Survival (PFS) was 6.2 (95%CI 3.7, 8.7) months and Overall Survival (OS) is currently estimated to be 15.5 (95%CI 6.0, 25.0) months. Of the reported adverse events (AEs) of any grade, 23% were related to cemiplimab and 31% to chemotherapy. Safety profile is in keeping with reported data on cisplatin based chemotherapy and immunotherapy. There were 2 grade 5 AEs, neither related to cemiplimab but 1 related to chemotherapy. 7 patients discontinued treatment due to an AE, 4 related to cemiplimab (14%). Conclusions: The EPIC-A Trial demonstrates the efficacy and safety of cemiplimab in combination with platinum-based chemotherapy as a treatment for la/mPC. Investigations into potential biomarkers and Quality of Life analysis is ongoing. These data support cisplatin based combination chemotherapy + cemiplimab as a first line SoC treatment option in this rare cancer. Clinical trial information: 95561634.

Efficacy and safety of ifosfamide and mesna in metastatic castration-resistant prostate cancer after taxane-based chemotherapy and novel hormonal therapy failure.

Journal of Clinical Oncology Chang Gon Kim, Yeo Gyeong Ko, Jongjin Yoon et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.174

174 Background: Limited treatment options exist for patients with metastatic castration-resistant prostate cancer (mCRPC) after the failure of taxane-based chemotherapy and novel hormonal therapy. Here, we report the safety and efficacy of ifosfamide and mesna in patients with mCRPC after the failure of taxane-based chemotherapy and novel hormonal therapy (NCT06236789). Methods: Patients with histologically confirmed prostate cancer who had failed taxane-based chemotherapy and novel hormonal therapy received ifosfamide 2,500 mg/m2 and mesna 1,500 mg/m2 on days 1–3, repeated every 21 days. Safety, objective response rate, disease control rate, reduction in serum prostate-specific antigen (PSA) concentration by >50% (PSA50) or >90% (PSA90), radiographic progression-free survival (rPFS), and overall survival (OS) were analyzed. Results: A total of 47 patients with mCRPC were included in the study. The median number of lines of treatment was 5 (range: 3–7). All patients were previously administered docetaxel and novel hormonal therapies including abiraterone (51.1%) and/or enzalutamide (61.7%). Thirty-eight patients (80.9%) were administered cabazitaxel. The objective response and disease control rates were 21.3% and 80.9%, respectively. PSA50 and PSA90 were achieved in 31.9% and 10.6%, respectively. During a median follow-up duration of 54.3 months, rPFS and OS were 5.0 and 9.0 months, respectively. All the patients experienced treatment-related adverse events of any grades; however, no new safety signs were detected. Genomic biomarker analysis revealed that alterations in the TP53 pathway were associated with inferior rPFS and OS. Conclusions: Ifosfamide and mesna showed appreciable efficacy and manageable safety profiles in heavily treated patients with mCRPC, warranting further investigation. Clinical trial information: NCT06236789 .

Second primary malignancy in bladder cancer: A retrospective population-based analysis.

Journal of Clinical Oncology Oboseh John Ogedegbe, Sakshi Bai, Olanipekun Lanny Ntukidem et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.676

676 Background: Bladder cancer is responsible for about 4% of cancers in the United States. It is the fourth most common cancer in men. A second primary malignancy is a significant complication in cancer survivors, with dire effects on morbidity and mortality. The data on second primary malignancies (SPM) in bladder cancer is limited. Therefore, we aim to evaluate and discuss this risk. Methods: We analyzed the Surveillance, Epidemiology, and End Results (SEER) database, comparing secondary cancer rates among bladder cancer cases diagnosed from 2000 to 2021. A second primary malignancy was defined as a malignancy developing six or more months after an index bladder cancer diagnosis. We used the SEER MP-SIR session to obtain the p-value, observed/Expected (O/E) ratio, and absolute excess risk (AER) per 10,000. Results: 238,358 bladder cancer cases from 2000-2021 met our inclusion criteria and were included in our study. Of these cases, 46,859 (19.7%) developed second primary malignancies. The mean age of SPM was 75.03 years. The risk of developing SPM was significantly higher than the general population, with an O/E ratio of 1.48 (CI 1.46-1.49, AER 99.85, p < 0.05). Most common SPMs included Hypopharynx (O/E ratio 1.3 CI 1.0-1.67, p < 0.05), Esophagus (O/E ratio 1.15 CI 1.05-1.26, p < 0.05), Liver (O/E ratio 1.14 CI 1.05-1.23, p < 0.05), Lung (O/E ratio 1.89 CI 1.85-1.93, p < 0.05), Vagina (O/E ratio 2.58 CI 1.71-3.73, p < 0.05, Prostate (O/E ratio 1.39 CI 1.36-1.42, p < 0.05, Acute Myeloid Leukemia (AML) (O/E ratio 1.58 CI 1.01-2.34, p < 0.05). Conclusions: Compared to the general population, there is a statistically significant increased risk of secondary primary malignancies in bladder cancer patients. Bladder cancer survivors would benefit from proactive screening modalities and follow-up for the development of SPM.

Efficacy and safety of immune checkpoint inhibitors (ICI) for the treatment of metastatic penile squamous cell carcinoma (mPSCC).

Journal of Clinical Oncology Tiewei Cheng, Timothy J. Schieber, Anna Clennon et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.4

4 Background: Metastatic penile squamous cell carcinoma (mPSCC) is a rare and aggressive malignancy with limited treatment options. Standard systemic therapies include paclitaxel, ifosfamide, cisplatin (TIP), fluorouracil and cisplatin (5-FU + cis), paclitaxel monotherapy and cetuximab. These regimens were evaluated as small single-arm studies. The HERCULES trial, a single-arm phase 2 clinical study, demonstrated the safety and efficacy of combining immunotherapy with chemotherapy, signaling a potential benefit of immunotherapy. Our retrospective analysis evaluates the safety and efficacy of single-agent immunotherapy at the University of Kansas and Aurora St. Luke’s Medical Center. Methods: We conducted a multicenter retrospective, IRB-approved study of mPSCC patients treated with single-agent immunotherapy from 2015 to 2023. Objective response rates were assessed per RECIST version 1.1, and progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Adverse events were graded per CTCAE version 5.0, with only grade 3+ immune-related adverse events being recorded. Results: Nine patients with mPSCC were included, with a median age of 75 years (range, 50-92). Over half (n=5) had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 2 or more, and most (n=8) had visceral metastasis. Single-agent immunotherapy was administered as first-line (n=3), second-line (n=4), and third-line or beyond (n=2). Pembrolizumab was used in six patients, with two receiving nivolumab and one cemiplimab. The objective response rate was 33.3% (n=3), including one complete response. Median PFS was 2.82 months (range, 1.0-14.3), and median OS was 4.3 months (range, 1.0-24.9). Patients who responded had PFS exceeding 12 months, with two still ongoing at data cutoff. No grade 3 or higher treatment-related adverse event has been observed during the treatment period. Additional analyses to correlate the response with HPV positivity are ongoing. Conclusions: Our findings suggest that single-agent immunotherapy can yield favorable response rates and durations in older and/or frail mPSCC patients. While our sample size is small and retrospective, response rates are comparable to those in the HERCULES trial (33.3% vs. 39.4% with chemoimmunotherapy). Notably, grade 3+ treatment-related adverse events were lower in our study compared to 51.4% of HERCULES patients. This underscores the potential of single-agent immunotherapy as a safe and effective option for this rare malignancy. Further prospective studies are needed to optimize treatment strategies for mPSCC.